Line and wrinkle injection profits rise

The popularity of Botox shows no sign of declining as Allergan – the company that manufactures the product – has just posted impressive fourth-quarter earnings for 2012. During the last three months of the year, the firm earned $324 million (£206 million), compared with $280 million during the same period in 2011.It is thought that the increase was aided not only by the use of Botox as a line and wrinkle treatment, but by growing sales of Botox as a solution for migraine headaches. Allergan also sells eye-care drugs which are proving to be popular. It was revealed that the company’s global sales rose by 7.4 per cent to reach $1.48 billion in the final quarter of 2012, which was in line with Wall Street expectations. The popularity of Botox has soared in recent years as it has become an alternative line and wrinkle treatment for those who want to retain their youthful appearance, but without undergoing invasive surgical procedures. Botox takes only a short time to administer and has virtually no recovery time, but lasts for around six months. Read the full story here: http://www.reuters.com/article/2013/02/05/allergan-results-idUSL1N0B54F620130205